Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients

Advances in Therapy

Volumn 27, Issue 1, 2010, Pages 48-55

  Fogari, Roberto ^a   Malamani, Gian ^a   Corradi, Luca ^a   Mugellini, Amedeo ^a   Preti, Paola ^a   Zoppi, Annalisa ^a   Derosa, Giuseppe ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Amlodipine; Ankle edema; Combination therapy; Hypertens ion; Olmesartan; Valsartan

Indexed keywords

AMLODIPINE; NORADRENALIN; OLMESARTAN; PLACEBO; VALSARTAN;

ADULT; AGED; ANKLE EDEMA; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NORADRENALIN BLOOD LEVEL; PLASMA RENIN ACTIVITY; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ADULT; AGED; AMLODIPINE; ANKLE JOINT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; EDEMA; FEMALE; HEART RATE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; NOREPINEPHRINE; PROSPECTIVE STUDIES; TETRAZOLES; VALINE;

EID: 77950692356     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-010-0002-0     Document Type: Article

References (36)

1. Weir MR. Incidence of pedel edema formation with dihydropyridine calcium channel blockers: issues and practical significance. J Clin Hypertens. 2003;5:330-335.
2. Fogari R. Ankle edema and sympathetic activation. Drugs. 2005;65(suppl. 2):21-27.
3. Chrisant SG. Proactive compared with passive adverse event recognition: calcium channel blockerassociated edema. J Clin Hypertens. 2008;10:716-722.
4. Sica DA. Pharmacotherapy review: calcium channel blockers. J Clin Hypertens. 2006;8:53-56.
5. Gustafsson D. Microvascular mechanisms involved in calcium antagonist edema formation. J Cardiovasc Pharmacol. 1987;10(suppl. 1):S121-S131.
6. Gustaffson D, Grande PO, Borgstrom P, Lindberg L. Effects of calcium antagonists on myogenic and neurogenic control of resistance and capacitance vessels in cat muscle. J Cardiovasc Pharmacol. 1988;12:413-422.
7. Salmasi AM, Belcaro G, Nicolaides AN. Impaired venoarteriolar reflex as a possible cause for nifedipine-induced ankle edema. Int J Cardiol. 1991;30:303-307.
8. Pedrinelli R, Dell'Olmo G, Melillo E, Mariani M. Amlodipine, enalapril and dependent leg edema in essential hypertension. Hypertension. 2000;35: 621-625.
9. Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Am J Hypertens. 2001;14:978-979.
10. Fogari R, Malamani GD, Zoppi A, et al. Comparative effect of lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients: a double-blind, randomized, parallelgroup study. Curr Ther Res Clin Exp. 2000;61:850-862.
11. Fogari R, Mugellini A, Zoppi A, et al. Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. Am J Hypertens. 2003;16:596-599.
12. Weir M, Rosenberg C, Fink JC. Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE-inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. Am J Hypertens. 2001;14: 963-968.
13. Messerli FH, Oparil S, Feng Z. Comparison of the efficacy and side-effects of combination therapy of angiotensin converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol. 2000;86:1182-1187.
14. Fogari R, Malamani GD, Zoppi A, et al. Effect of benazepril addition to amlodipine on ankle edemaand subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens. 2003;17:207-212.
15. Fogari R, Malamani GD, Zoppi A, et al. Effect on the development of ankle edema of adding delapril to manidipine in patients with mild to moderate essential hypertension: a three-way crossover study. Clin Ther. 2007;29:413-418.
16. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebocontrolled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29:563-580.
17. de la Sierra A. Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system. J Hum Hypertens. 2009;23:503-511.
18. Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens. 2007;21:220-224.
19. Rea RF, Eckberg DL, Fritsch JM, Goldstein DS. Relation of plasma norepinephrine and sympathetic traffic during hypotension in humans. Am J Physiol. 1990;258:R982-R986.
20. Abdelrahman AM, Burrel LM, Johnston CI. Blockade of the renin-angiotensin system at different sites: effect on renin, angiotensin, and aldosterone. J Hypertens. 1993;11(suppl. 3):S49-S52.
21. Hansson L, Hedner T, Dahlof B. Prospective, randomised, open, blinded end-point (PROBE) study: a novel design for intervention trials. Blood Press. 1992;1:113-114.
22. Schindler C, Brosnihan KB, Ferrario CM, et al. Comparison of inhibitory effects of irbesartan and atorvastatin treatment on the Renin Angiotensin System (RAS) in veins: a randomized double-blind crossover trial in healthy subjects. J Clin Pharmacol. 2007;47:112-120.
23. Remie R, Zaagsma J. A new technique for the study of vascular presynaptic receptors in freely moving rats. Heart Circ Physiol. 1986;251:4463-4467.
24. Hjemdahl P. Plasma catecholamines as markers for sympathoadrenal activity in human primary hypertension. Pharmacol Toxicol. 1988;63 (suppl. 1):S27-S31.
25. Bramlage P, Schindler C. Differences in pharmacology and their translation into differences in clinical efficacy-a comparison of the renin angiotensin blocking agents irbesartan and losartan. Expert Opin Pharmacother. 2009 Dec 23 [Epub ahead of print].
26. Fogari R, Zoppi A, Mugellini A, et al. Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controller by monotherapy. Adv Ther. 2006;23:680-695.
27. Rohatagi S, Lee J, Shenouda M, et al. Pharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoximil in separate dosage forms and as a fixeddose combination. J Clin Pharmacol. 2008;48: 1309-1322.
28. Grassi G, Esler M. How to assess sympathetic activity in humans. J Hypertens. 1999;17:719-734.
29. Fogari R, Mugellini A, Zoppi A, et al. A doubleblind, crossover study of the antihypertensive efficacy of angiotensin II-receptor antagonists and their activation of the renin-angiotensin system. Curr Ther Res. 2000;61:669-679.
30. Fogari R, De Gasparo M. Addressing those two that go together: the angiotensin II receptors and their role in blood flow regulation. Blood Press. 2001;10:6-15.
31. Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 2001;103:904-912.
32. Van Liefde I, Vauquelin G. Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism. Mol Cell Endocrinol. 2009;302:237-243.
33. Fernandes L, Loiola RA, Tostes RCA, Nigro D, Fortes ZB, De Carvalho MHC. Angiotensin II-induced venoconstriction involves both AT1 and AT2 receptors and is counterbalanced by nitric oxide. Peptides. 2005;26:2458-2463.
34. Pelet C, Mironneau C, Rakotoarisoa L, Neuilly G. Angiotensin II receptor subtypes in portal vein smooth muscle. Eur J Pharmacol. 1995;279:15-24.
35. Tabizchi R, King KA, Pang CC. Direct and indirect effects of angiotensin II on venous tone in conscious rats. Eur J Pharmacol. 1992;219:141-145.
36. Rothe CF, Maass-Moreno R. Active and passive liver microvascular responses from angiotensin, endothelin, norepinephrine and vasopressin. Am J Physiol. 2000;279:H1147-H1156.